Selected References: Meissner WG, Remy P, Giordana C, Maltte D, Derkinderen P, Houto JL, Anheim M, Benatru I, Boraud T, Brefel-Courbon C, Carrire N, Catala H, Colin O, Corvol JC, Damier P, Dellapina E, Devos D, Drapier S, Fabbri M, Ferrier V, Foubert-Samier A, Frismand-Kryloff S, Georget A, Germain C, Grimaldi S, Hardy C, Hopes L, Krystkowiak P, Laurens B, Lefaucheur R, Mariani LL, Marques A, Marse C, Ory-Magne F, Rigalleau V, Salhi H, Saubion A, Stott SRW, Thalamas C, Thiriez C, Tir M, Wyse RK, Benard A, Rascol O
Researchers assign participants to dose groups, monitor safety, and adjust study medicine only under defined rules
In addition to weight loss benefits, GLP-1 therapy is an effective treatment for type 2 diabetes
Is anyone aware whether or not diabetes folks will be eligible
If eligible, the plan may include medication options, nutrition, physical activity, follow-up care, and insurance documentation support
Very cheap retatrutide exists